Brooks Laboratories
NSE: BROOKS · ISIN INE650L01011 · Healthcare
₹66.06+0.10 (+0.15%)
Monday 9 November, 12:03 IST. Delayed. Source: Yahoo Finance.
Price chart
₹66.06 +0.10 (+0.15%) today
The day
- Previous close
- ₹65.96
- Open
- ₹67.90
- Day high
- ₹68.90
- Day low
- ₹65.25
Listed on NSE since 5 September 2011.
Key numbers
- Market value
- ₹186.32 Cr
- P/E (trailing)
- 14.09
- EPS (trailing)
- ₹4.49
- Price to book
- 1.52
- Dividend yield
- 0.00%
- Debt to equity
- 0.07
- Profit margin
- 15.9%
- Beta
- 1.04
- Volume today
- 14,545
- Average volume
- 97,160
Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.
Revenue and profit
| Year | Revenue | Net profit |
|---|---|---|
| FY23 | ₹62.48 Cr | ₹-20.89 Cr |
| FY24 | ₹79.01 Cr | ₹-19.59 Cr |
| FY25 | ₹82.19 Cr | ₹-9.97 Cr |
| FY26 | ₹85.38 Cr | ₹24.58 Cr |
Source: Yahoo Finance, from annual reports. Consolidated where reported. EPS before FY24 is not shown: the share count changed (a bonus, split or merger), so earlier figures would not compare.
Quarterly results
| Quarter | Revenue | Net profit | Profit vs year ago |
|---|---|---|---|
| Q2 FY27Jul–Sep 2026 | ₹19 Cr | ₹68 Cr | +747.6% |
| Q1 FY27Apr–Jun 2026 | ₹23 Cr | ₹-2 Cr | −118.6% |
| Q4 FY26Jan–Mar 2026Audited | ₹20 Cr | ₹1 Cr | – |
| Q3 FY26Oct–Dec 2025 | ₹17 Cr | ₹5 Cr | – |
| Q2 FY26Jul–Sep 2025 | ₹23 Cr | ₹8 Cr | – |
| Q1 FY26Apr–Jun 2025 | ₹26 Cr | ₹10 Cr | – |
Source: Brooks Laboratories’s results filed with NSE, consolidated (the whole group). Net profit is the share of Brooks Laboratories’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.
Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.
Balance sheet
| As on | September 2026 | March 2026 |
|---|---|---|
| Fixed assets | ₹17 Cr | ₹15 Cr |
| Investments | ₹87 Cr | ₹92 Cr |
| Inventories | ₹11 Cr | ₹11 Cr |
| Owed by customers | ₹18 Cr | ₹16 Cr |
| Cash and equivalents | ₹71.07 L | ₹7 Cr |
| Total assets | ₹218 Cr | ₹148 Cr |
| Borrowings | ₹5 Cr | ₹7 Cr |
| Total liabilities | ₹29 Cr | ₹26 Cr |
| Shareholders’ equity | ₹188 Cr | ₹123 Cr |
Source: Brooks Laboratories’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.
About Brooks Laboratories
Brooks Laboratories Limited operates as a pharmaceutical manufacturer in India and internationally. It operates in two segments, Manufacturing and Trading. The company offers liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; and B-Lactam and cephalosporin tablets, dry powder syrups, and injections. It is also involved in loan-licensing business relating to pharmaceutical products, ingredients, and intermediaries; and trading in pharmaceutical products, ingredients, and intermediaries. In addition, the company offers oncology products and hormonal injections; and formulations for therapeutic areas comprising antibiotic, pain management, controlled drugs. It exports its products to Afghanistan, Yemen, Kosovo, Bolivia, Guatemala, Turkmenistan, Nigeria, Lebanon, Mauritius, Sudan, Madagascar, the Democratic Republic of Congo, Angola, Mozambique, Latin America, and Africa. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.
- Industry
- Drug Manufacturers - Specialty & Generic
- Based in
- Mumbai
- Employees
- 347
Company website · Profile: Yahoo Finance
In the news
All newsNo headlines name Brooks Laboratories in the last day or two.
Dividends and corporate actions
All companies- Annual General Meeting
Action · ex-date 12 September 2024
- Annual General Meeting
Action · ex-date 14 September 2023
- Rights 1:16 @ Premium Rs 65/-
Right · ex-date 28 July 2023
- Annual General Meeting
Action · ex-date 22 September 2022
- Annual General Meeting
Action · ex-date 21 September 2021
- Annual General Meeting
Action · ex-date 18 September 2020
- Rights 9:20 @ Premium Rs 10/-
Right · ex-date 11 February 2020 · record date 12 February 2020
- Annual General Meeting
Action · ex-date 17 September 2019
Source: NSE. Latest first, 8 of 15.
Information only, not investment advice. Prices are delayed.